Literature DB >> 31694841

Sphingolipids in COPD.

Raja Chandra Chakinala1, Akshay Khatri2, Kriti Gupta3, Kengo Koike4, Oleg Epelbaum5.   

Abstract

Sphingolipids are a distinct class of lipid molecules widely found in nature, principally as cell membrane constituents. After initial uncertainty about their function, sphingolipids have been increasingly recognised to be metabolically active entities involved in many biological processes, including the control of inflammation. Their role as mediators of inflammation may have significant implications for a range of lung diseases in which inflammation is a central element of pathogenesis. Chronic obstructive pulmonary disease (COPD), a highly prevalent and morbid condition predominantly affecting cigarette smokers, is a prime example of a respiratory illness with an inflammatory component. Understandably, sphingolipids have received growing attention for their increasingly demonstrated role in the pathophysiology of COPD. The present review aims to be among the first to focus exclusively on the connection between sphingolipids and lung inflammation in COPD, providing the reader with a clinically oriented synopsis of this intriguing association.
Copyright ©ERS 2019.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31694841     DOI: 10.1183/16000617.0047-2019

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  8 in total

1.  Regulatory roles of external cholesterol in human airway epithelial mitochondrial function through STARD3 signalling.

Authors:  Liyang Li; Yifei Liu; Xuanqi Liu; Nannan Zheng; Yutong Gu; Yuanlin Song; Xiangdong Wang
Journal:  Clin Transl Med       Date:  2022-06

Review 2.  The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.

Authors:  Mohamed Abu-Farha; Thangavel Alphonse Thanaraj; Mohammad G Qaddoumi; Anwar Hashem; Jehad Abubaker; Fahd Al-Mulla
Journal:  Int J Mol Sci       Date:  2020-05-17       Impact factor: 5.923

3.  Epigenome-wide association study of DNA methylation and adult asthma in the Agricultural Lung Health Study.

Authors:  Thanh T Hoang; Sinjini Sikdar; Cheng-Jian Xu; Mi Kyeong Lee; Jonathan Cardwell; Erick Forno; Medea Imboden; Ayoung Jeong; Anne-Marie Madore; Cancan Qi; Tianyuan Wang; Brian D Bennett; James M Ward; Christine G Parks; Laura E Beane-Freeman; Debra King; Alison Motsinger-Reif; David M Umbach; Annah B Wyss; David A Schwartz; Juan C Celedón; Catherine Laprise; Carole Ober; Nicole Probst-Hensch; Ivana V Yang; Gerard H Koppelman; Stephanie J London
Journal:  Eur Respir J       Date:  2020-09-03       Impact factor: 16.671

4.  Mechanistic analysis and significance of sphingomyelinase-mediated decreases in transepithelial CFTR currents in nHBEs.

Authors:  Kirsten A Cottrill; Vincent D Giacalone; Camilla Margaroli; Robert J Bridges; Michael Koval; Rabindra Tirouvanziam; Nael A McCarty
Journal:  Physiol Rep       Date:  2021-09

Review 5.  Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease.

Authors:  Stanislav Kotlyarov; Aleksei Bulgakov
Journal:  Cells       Date:  2021-11-01       Impact factor: 6.600

6.  Alterations in bile acids as metabolic signatures in the patients with human adenovirus type 7 infection.

Authors:  Wen Xu; Juan Du; Ting-Ting Wei; Lin-Yi Chen; Xin-Xin Yang; Tu Bo; Han-Yu Liu; Ming-Zhu Xie; Tian-Shuo Zhao; Jun-Lian Yang; Fuqiang Cui; Wei-Wei Chen; Qing-Bin Lu
Journal:  Front Med (Lausanne)       Date:  2022-09-07

7.  Metabolomics Reveals Dysregulated Sphingolipid and Amino Acid Metabolism Associated with Chronic Obstructive Pulmonary Disease.

Authors:  Jeeyoung Kim; Bharathi Suresh; Myoung Nam Lim; Seok-Ho Hong; Kye-Seong Kim; Ha Eun Song; Hyo Yeong Lee; Hyun Ju Yoo; Woo Jin Kim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-09-21

Review 8.  Neutral sphingomyelinase-2 and cardiometabolic diseases.

Authors:  Sardar Sindhu; Yat Hei Leung; Hossein Arefanian; S R Murthy Madiraju; Fahd Al-Mulla; Rasheed Ahmad; Marc Prentki
Journal:  Obes Rev       Date:  2021-03-18       Impact factor: 9.213

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.